This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/518623-france-pm-astrazeneca-covid-vaccine/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Prime Minister Jean Castex gets Covid-19 vaccine live on air as France resumes rollout after blood-clot fears | Prime Minister Jean Castex gets Covid-19 vaccine live on air as France resumes rollout after blood-clot fears |
| (6 months later) | |
| French Prime Minister Jean Castex received his AstraZeneca Covid-19 jab on live TV Friday as the country restarted its use of the vaccine. Earlier, the EU's drug regulator said it was safe, despite fears it causes blood clotting. | French Prime Minister Jean Castex received his AstraZeneca Covid-19 jab on live TV Friday as the country restarted its use of the vaccine. Earlier, the EU's drug regulator said it was safe, despite fears it causes blood clotting. |
| "I didn't feel anything," the 55-year-old said at the Begin military hospital in Paris as he sought to allay fears that the vaccine was unsafe. France was among a dozen European Union nations to pause its rollout of the jab. | "I didn't feel anything," the 55-year-old said at the Begin military hospital in Paris as he sought to allay fears that the vaccine was unsafe. France was among a dozen European Union nations to pause its rollout of the jab. |
| Paris announced on Thursday it would resume administration of the AstraZeneca vaccine following a review by the European Medicines Agency (EMA), which found it was not associated with an increase in the overall risk of blood clots. | Paris announced on Thursday it would resume administration of the AstraZeneca vaccine following a review by the European Medicines Agency (EMA), which found it was not associated with an increase in the overall risk of blood clots. |
| The EU regulator's safety committee said the vaccine's benefits "continue to outweigh the risk of side effects," despite a possible link to "very rare" cases of blood clots. | The EU regulator's safety committee said the vaccine's benefits "continue to outweigh the risk of side effects," despite a possible link to "very rare" cases of blood clots. |
| According to EMA, some 20 million people in the UK and European Economic Area had received the vaccine as of March 16. | According to EMA, some 20 million people in the UK and European Economic Area had received the vaccine as of March 16. |
| Of the total, the agency said it had only seen seven cases of blood clots in multiple blood vessels and 18 cases of CVST, where a clot stops blood draining from the brain. | Of the total, the agency said it had only seen seven cases of blood clots in multiple blood vessels and 18 cases of CVST, where a clot stops blood draining from the brain. |
| France's return to the AstraZeneca vaccine will only be for those aged 55 and over, because blood clots had only been seen in people under 55, the French drug regulator Haute Autorité de Santé said. | France's return to the AstraZeneca vaccine will only be for those aged 55 and over, because blood clots had only been seen in people under 55, the French drug regulator Haute Autorité de Santé said. |
| Germany, Italy and Spain were among several other EU nations to announce their backing of the jab late on Thursday | Germany, Italy and Spain were among several other EU nations to announce their backing of the jab late on Thursday |
| However, EU member state Finland has suspended its use as health officials there investigate two possible cases of blood clots, the Finnish Institute for Health and Welfare said on Friday. | However, EU member state Finland has suspended its use as health officials there investigate two possible cases of blood clots, the Finnish Institute for Health and Welfare said on Friday. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |